
Jul 12, 2026
Whole Genome Interpretation Services
Genomics and omics analysis spans the full journey from raw sequencing output to clinically or scientifically actionable findings. Teams working with next-generation sequencing data rely on validated pipelines for alignment, variant calling, and downstream interpretation — workflows that must be reproducible, auditable, and scalable to large sample cohorts.
As data complexity grows, so does the need for tools that integrate multiple molecular layers. Single-cell and spatial approaches generate high-dimensional datasets where cell-type resolution, trajectory inference, and cross-modality integration are central analytical challenges. Connecting transcriptomic, epigenomic, and proteomic readouts within a coherent analytical framework is now a core requirement for many research programmes.
In clinical and translational contexts, variant annotation and classification against curated evidence databases directly informs diagnostic reporting and therapeutic decision-making. Underpinning all of this is the need for robust data infrastructure — platforms capable of managing large-scale multi-omics datasets, orchestrating compute workflows, and supporting secure collaboration across institutions and jurisdictions.
Cloud-based and federated platforms for multi-omics data management, large-scale workflow orchestration, and secure cross-organisation genomic data collaboration.
Platforms for end-to-end processing of next-generation sequencing data -- alignment, variant calling, RNA-seq, epigenomics, and amplicon analysis -- through validated pipelines.
Platforms for integrated analysis and visualisation of single-cell, spatial transcriptomics, and multi-omics datasets including scRNA-seq, ATAC-seq, and proteomics.
Tools that annotate and classify genomic variants from NGS data -- connecting mutations to clinical evidence, disease associations, and therapeutic relevance -- for diagnostic decision-making and clinical reporting.
Different analysts applying different evidence thresholds leads to conflicting clinical interpretations of the same variant.
NGS workflows run on different infrastructure often produce results that cannot be directly compared or audited.
Combining data from RNA-seq, ATAC-seq, and proteomics requires harmonised processing that most general-purpose tools cannot handle.
Single-cell datasets with millions of cells quickly exceed the memory and processing capacity of standard workstations.
Regulatory and consent constraints make cross-organisation data sharing technically and legally complex without federated infrastructure.
Moving from a curated variant list to a structured, evidence-backed clinical report requires specialised annotation and formatting workflows.
Diagnostic labs use these tools when translating sequencing results from targeted gene panels into structured clinical variant reports.
Research teams apply single-cell analysis when understanding clonal architecture and transcriptional diversity within tumour biopsies.
Consortium projects rely on federated data platforms when harmonising genomic datasets generated across multiple sequencing centres.
Groups running ATAC-seq or ChIP-seq experiments require pipelines purpose-built for peak calling and regulatory element annotation.
Clinical teams investigating undiagnosed rare diseases use variant interpretation tools to prioritise candidate mutations against disease databases.
Translational researchers adopt spatial analysis platforms when mapping gene expression patterns to tissue architecture in situ.





Spatial transcriptomics and tissue-based omics analyses increasingly intersect with digital pathology image data and workflows.
Genomic and multi-omics findings directly inform target identification and molecular design decisions in early drug discovery.
Clinical genomics reporting depends on integration with patient records, phenotypic data, and health data systems.
Pharmacogenomic data from omics studies feeds into drug safety assessment and population PK/PD modelling.
Variant and gene-level findings are routinely cross-referenced against literature and biological knowledge bases.

Jul 12, 2026
Whole Genome Interpretation Services

Jul 12, 2026
En Carta Diagnostics secures 5 million euros for home testi

Jul 9, 2026
Alchemab extends Series A with £25m from British Business Bank

Jul 8, 2026
Lantern Pharma Launches ZetaOmics, an AI-Powered Computational Biology Platform

Jul 7, 2026
Strand Life Sciences Bags Patent for AI Cancer Detection Tech

Jul 7, 2026
Reliance's Strand Life Sciences Secures Indian Patent